Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.
. Group II: 10 mg po qd, Group III: 12 mg po qd;
Combined chemotherapy:
Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Patients With Non-small Cell Lung Cancer

Simultaneous chemoradiotherapy for An Luo

The second affiliated Hospital of Xi'an Jiaotong University

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer

complete response(CR)+partial response(PR) according to RECIST 1.1

overall survival is defined as the time from randomization to death from any cause

progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause

Second Affiliated Hospital of Xi'an Jiaotong University

Tang-Du Hospital

Xijing Hospital

First Affiliated Hospital Xi'an Jiaotong University

Shaanxi Provincial Cancer Hospital

Shaanxi Provincial People's Hospital

Experimental group: anlotinib (D1-14, d22-36, followed by 21 days cycle, taking medicine for 2 weeks, stopping for 1 week).
Group 1: 8mg po qd, Group 2: 10mg po qd, Group 3: 12mg po qd;
Combined chemotherapy:
Cisplatin + etoposide or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + pemetrexed (non-squamous cell carcinoma). Simultaneous radiotherapy: 3D-CRT or IMRT external radiotherapy (60-66 Gy, 2.0 Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.

Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.

Regimen A (R-CODOX-M Chemotherapy)

Regimen B (Rituximab and IVAC Chemotherapy)

Total

Sex: Female, Male

Region of Enrollment

Overall Survival (OS) at 1 Year

Complete Response Rate

Failure-free Survival (FFS)

Event-free Survival (EFS)

Toxicity

Incidence of Infection-related Deaths

Correlation of C-flip Expression, p53 Mutations, and Multidrug Resistance Expression With OS, FFS, and EFS

Utility of Flow Cytometry in Detecting Leptomeningeal Disease

Degree of Disconcordance Between Flow Cytometry and CNS Cytology Results

Biologic and Prognostic Significance of Epstein-Barr Virus (EBV) at Diagnosis and Correlation With OS, FFS, and EFS

Correlation of EBV Load Measurements With OS, FFS, and EFS

Overall Study

Jeannette Lee, Ph.D.

Lymphoma

filgrastim

pegfilgrastim

rituximab

cyclophosphamide

cytarabine

doxorubicin hydrochloride

etoposide

ifosfamide

leucovorin calcium

liposomal cytarabine

methotrexate

therapeutic hydrocortisone

vincristine sulfate

Rebecca and John Moores UCSD Cancer Center

USC/Norris Comprehensive Cancer Center and Hospital

UCLA Clinical AIDS Research and Education (CARE) Center

UCSF Medical Center at Parnassus

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Beth Israel Deaconess Medical Center

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

Albert Einstein Cancer Center at Albert Einstein College of Medicine

Memorial Sloan-Kettering Cancer Center

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia

Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center

West Virginia University Health Sciences Center - Charleston

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma

etoposide/tūska

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne